Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sparlon review

Executive Summary

Cephalon's attention deficit/hyperactivity disorder drug Sparlon will be reviewed by FDA's Psychopharmacologic Drugs Advisory Committee on March 23. The meeting will follow two advisory committee reviews on the safety of ADHD drugs in February and March. Sparlon contains the same active ingredient as Cephalon's Provigil, which is approved for narcolepsy. The modafinil sNDA for ADHD in children and adolescents ages 6-17 was deemed "approvable" by FDA on Oct. 20 pending resolution of labeling issues (1"The Pink Sheet" Jan. 2, 2006, p. 12). The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m. [Editor's note: To 2watch a webcastor order a video/DVD of this or any other meeting, visit]...

You may also be interested in...

Cephalon’s 2006 Marketing Focus: Sparlon For ADHD, Nuvigil For Narcolepsy

Cephalon will position its attention deficit hyperactivity disorder therapy Sparlon (modafinil) as a "non-traditional" stimulant for inattentive patients with mild-to-moderate hyperactivity

US High Court Punts On ‘Objective Falsity’ FCA Standard

Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.

White House To Deliver 25 Million Face Masks To Low-Income Americans

The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts